Miller L J
Department of Psychiatry, University of Chicago.
Psychiatr Med. 1991;9(2):275-98.
The treatment of major psychiatric disorders during pregnancy is becoming an increasing challenge for the clinician as fertility rates rise among mentally ill women. When prescribing psychotropic medication, the risk/benefit analysis comes to include the risks of the medication to the fetus, special risks to the mother because of the pregnant state, and the risks to both mother and fetus of the untreated psychiatric disorder. This article will review what is known about the risks to mother and fetus of antipsychotic, antidepressant, anxiolytic, mood stabilizing and antiparkinsonian agents, and will present treatment strategies designed to minimize those risks.
随着患有精神疾病的女性生育率上升，孕期主要精神障碍的治疗对临床医生来说正成为一项日益艰巨的挑战。在开具精神类药物处方时，风险/获益分析开始涵盖药物对胎儿的风险、怀孕状态给母亲带来的特殊风险，以及未经治疗的精神障碍对母亲和胎儿双方的风险。本文将综述关于抗精神病药、抗抑郁药、抗焦虑药、心境稳定剂及抗帕金森病药物对母亲和胎儿风险的已知情况，并提出旨在将这些风险降至最低的治疗策略。
